

Table 2: Lead-in, Initiation, and Maintenance for Monthly (every 4 weeks) CAB/RPV LA Dosing**Table 3: Lead-in, Initiation, and Maintenance for Bimonthly (every 8 weeks) CAB/RPV LA Dosing**

Table 2: Lead-in, Initiation, and Maintenance for Monthly (every 4 weeks) CAB/RPV LA Dosing [a]		
Timing	Dosing and Administration	Comments
Week 0 (month 0)	CAB 30 mg/RPV 25 mg once daily by mouth with a meal for 4 weeks	Optional oral medication lead-in
Week 4 (month 1)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Initiation dose: Administer on last day of oral lead-in or prior suppressive ART regimen
Week 8 (month 2) and every 4 weeks (every 1 month) thereafter	CAB 400 mg (2 mL)/RPV 600 mg (2 mL) IM injection	Maintenance dose: Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections in full guideline)
Abbreviations: ART, antiretroviral therapy; CAB, cabotegravir (Vocabria); CAB/RPV LA, long-acting injectable cabotegravir/rilpivirine (Cabenuva); IM, intramuscular; RPV, rilpivirine (Edurant). Note: a. [FDA 2022]		

Table 3: Lead-in, Initiation, and Maintenance for Bimonthly (every 8 weeks) CAB/RPV LA Dosing [a,b]		
Timing	Dosing and Administration	Comments
Week 0 (month 0)	CAB 30 mg/RPV 25 mg once daily by mouth with a meal for 4 weeks	Optional oral medication lead-in
Week 4 (month 1)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Initiation dose: Administer on last day of oral lead-in or prior suppressive ART regimen
Week 8 (month 2)	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Maintenance dose: Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections in full guideline)
Week 16 (month 4) and every 8 weeks (every 2 months) thereafter	CAB 600 mg (3 mL)/RPV 900 mg (3 mL) IM injection	Maintenance dose: Administer within 7 days before or after scheduled date (see Managing Missed or Delayed Injections in full guideline)
Abbreviations: ART, antiretroviral therapy; CAB, cabotegravir (Vocabria); CAB/RPV LA, long-acting injectable cabotegravir/rilpivirine (Cabenuva); IM, intramuscular; RPV, rilpivirine (Edurant). Notes: a. [ViiV Healthcare 2022] b. [FDA 2022]		

References

- FDA. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use. 2022 Mar. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf [accessed 2025 Jun 5]
- ViiV Healthcare. ViiV Healthcare announces US FDA approval of cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment. 2022 Feb 1. <https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/january/viiv-healthcare-announces-fda-approval-of-cabenuva-for-use-every-two-months/> [accessed 2025 May 14]